Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

06.05.19	FDA approves Roche's Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment (GlobeNewswire)
29.04.19	New Roche data at the 2019 AAN Annual Meeting showcase breadth and promise of neuroscience portfolio (GlobeNewswire)
26.04.19	Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)
23.04.19	Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy (GlobeNewswire)
17.04.19	Roche startet mit starkem Umsatzwachstum ins Jahr 2019 und erhöht den Ausblick für das Gesamtjahr (GlobeNewswire)
17.04.19	Roche reports a strong start in 2019 and raises the outlook for the full-year (GlobeNewswire)
03.04.19	Roche and Spark Therapeutics, Inc. announce withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc. (GlobeNewswire)
01.04.19	Roche's ipatasertib in combination with Tecentriq and chemotherapy shows promising anti-tumour activity in triple-negative breast cancer in early phase trial (GlobeNewswire)
19.03.19	FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer (GlobeNewswire)
15.03.19	European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease (GlobeNewswire)
14.03.19	European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors (GlobeNewswire)
11.03.19	Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane (GlobeNewswire)
11.03.19	FDA grants Roche's Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
08.03.19	European Commission approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer (GlobeNewswire)
07.03.19	Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash (GlobeNewswire)
07.03.19	Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions (GlobeNewswire)
05.03.19	Roche Annual General Meeting 2019 (GlobeNewswire)
05.03.19	Roche Generalversammlung 2019 (GlobeNewswire)
28.02.19	FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers (GlobeNewswire)
25.02.19	Roche enters into definitive merger agreement to acquire Spark Therapeutics (GlobeNewswire)
19.02.19	FDA grants Priority Review to Roche's personalised medicine entrectinib (GlobeNewswire)
19.02.19	FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma (GlobeNewswire)
06.02.19	Roche joins the World Federation of Hemophilia Humanitarian Aid Program (GlobeNewswire)
05.02.19	Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment (GlobeNewswire)
01.02.19	CHMP recommends EU approval of Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors (GlobeNewswire)
01.02.19	CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer (GlobeNewswire)
31.01.19	Roche mit sehr gutem Jahresergebnis für 2018 (GlobeNewswire)
31.01.19	Roche reports very strong results in 2018 (GlobeNewswire)
30.01.19	Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) - other company programmes in AD continue (GlobeNewswire)
17.12.18	PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) (GlobeNewswire)
10.12.18	Neues Mitglied zur Wahl in den Verwaltungsrat von Roche vorgeschlagen (GlobeNewswire)
10.12.18	New member proposed for election to Roche Board of Directors (GlobeNewswire)
10.12.18	Änderungen in der Konzernleitung von Roche (GlobeNewswire)
10.12.18	Changes to the Roche Corporate Executive Committee (GlobeNewswire)
07.12.18	FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer (GlobeNewswire)
05.12.18	Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment (GlobeNewswire)
05.12.18	FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer (GlobeNewswire)
04.12.18	New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia (GlobeNewswire)
03.12.18	Roche's Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors (GlobeNewswire)
03.12.18	Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma (GlobeNewswire)
21.11.18	Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy (GlobeNewswire)
13.11.18	FDA grants priority review to Roche's Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
01.11.18	Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting (GlobeNewswire)
01.11.18	Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities (GlobeNewswire)
01.11.18	Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia (GlobeNewswire)
29.10.18	Neue Daten der STAIRWAY-Studie zeigen mögliche längere Wirkdauer für Faricimab von Roche bei neovaskulärer altersbedingter Makuladegeneration (nAMD) (GlobeNewswire)
29.10.18	New STAIRWAY study data shows potential for extended durability with Roche's faricimab in neovascular age-related macular degeneration (nAMD) (GlobeNewswire)
24.10.18	Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza (GlobeNewswire)
22.10.18	Roche's Alecensa (alectinib) significantly reduced the risk of disease worsening or death as first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer (GlobeNewswire)
22.10.18	Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-small cell lung cancer live significantly longer compared to chemotherapy alone (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

21.11.24		Aufschläge in New York: Dow Jones letztendlich in der Gewinnzone
21.11.24		Freundlicher Handel: TecDAX letztendlich im Plus
21.11.24		Gewinne in Frankfurt: Letztendlich Pluszeichen im DAX
21.11.24		Börse Europa: Euro STOXX 50 letztendlich in der Gewinnzone
21.11.24		Zuversicht in Frankfurt: LUS-DAX beendet die Donnerstagssitzung im Plus
21.11.24		SDAX aktuell: SDAX zum Handelsende auf grünem Terrain
21.11.24		Gute Stimmung in Zürich: Anleger lassen SPI schlussendlich steigen